Dr. Lakhmir Chawla
Dr. Chawla is currently the Chief Medical Officer of Silver Creek Pharmaceuticals and previously was CMO at La Jolla Pharmaceutical Company (LJPC). Prior to joining LJPC, Dr. Chawla was a Professor of Medicine at the George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine as well as in the Department of Medicine, Division of Renal Diseases and Hypertension.
Dr. Chawla was previously the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. This initial study was the first RCT of angiotensin II in shock and led to the initiation of La Jolla’s ATHOS 3 trial, a Phase 3 clinical trial of LJPC-501, which assessed angiotensin II for the treatment of catecholamine-resistant hypotension (shock). The ATHOS-3 Trial was published in the New England Journal of Medicine in 2017 and helped support the FDA approval of GIAPREZA (angiotensin II) on December 2017 and EMA approval in August 2019. Thereafter, Dr. Chawla oversaw the Medical Affairs launch and commercialization of GIAPREZA.
Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI), acute kidney disease (AKD), and shock. He remains an active investigator in the fields of AKI biomarkers, AKI risk prediction, AKI therapeutics and chronic kidney disease caused by AKI.
Dr. Chawla is also the author of over 150 peer-reviewed publications and a recipient of the International Vicenza Award for Critical Care Nephrology; an award that recognizes individuals who have made seminal clinical research advancements that have significantly improved the care of critically ill patients with AKI and have been adopted worldwide.
Dr. Michael Harper
Michael D. Harper, MD is an Intensivist with MedStar Washington Hospital Center in Washington, D.C. and is boarded in both Emergency Medicine and Critical Care medicine. He has extensive experience in the ICU care of thoracic and abdominal transplant recipients, patients receiving cardiothoracic surgery, and in the placement and management of ECMO both for ARDS and cardiogenic shock.
He has spent the last five years helping to manage a statewide ECMO referral system in the Midwest, specializing in the deployment of mobile ECMO teams. He has previously served on the conference planning committee of the Extracorporeal Life Support Organization, and currently is serving as a member of a workforce dedicated to studying shock in the thoracic transplant patient population with the American Society of Transplantation. His clinical and research interests align at the vital physiologic point of impaired oxygen delivery: a hallmark of both ARDS and shock states.
Dr. Michael Mohning
Dr. Michael Mohning is a Pulmonary and Critical care physician at National Jewish Health in Denver, Colorado. He serves as the Medical Director for their Pulmonary Physiology Unit where all pulmonary physiology and exercise testing is performed.
In addition to his interests in pulmonary and exercise physiology, he subspecializes in the diagnosis and treatment of patients with Interstitial Lung Disease (ILD). He has served as an investigator on numerous clinical trials in the field of ILD.
Dr. Michael Roshon
Dr. Michael Roshon received his MD and PhD degrees from Vanderbilt University and is board certified in Emergency Medicine. He has served as the team physician for a number of professional cycling teams for nearly 2 decades, operating at the highest levels of the sport including medical support for Grand Tour and World Tour events. He currently serves as the Chief Medical officer for USA Cycling and as the Chief of the Medical Staff for a large hospital system in Colorado Springs, CO.
During his PhD work, Dr. Roshon studied retroviruses and due to this background in virology he has had a long-standing interest in pandemic viruses and their epidemiology. This background prepared him to serve as the lead medical specialist for his hospital’s COVID-19 task force, leading the development of clinical protocols, and guidelines to prevent transmission in the healthcare setting. While continuing his work on the front lines of the response as an Attending Physician in the Emergency Department, Dr. Roshon also served as an advisor to the El Paso County Health Department’s COVID-19 response, and has published several peer-reviewed papers related to modulating the immune response to SARS CoV-2, including an article in Science Immunology in June 2020. Currently Dr. Roshon is a principal investigation on 3 randomized controlled trials on investigation novel therapeutics for COVID-19, including trials sponsored by the National Institute of Allergy and Infectious Disease.
Dr. Roshon’s first-hand experience in the care of athletes and his background in virology has uniquely prepared him to understand the intricacies of planning for sporting events during this pandemic.